Randomisation in a clinical trial: is it feasible in the Ebola crisis? If it is, then which method is suitable?
Randomisation is an integral component of any sensible clinical trial. Randomisation is the only way we can be sure that the patients have been allocated into the treatment arms with as minimum bias as possible, and that the treatment arms are similar before the start of the trial. The randomisation...
Main Author: | Jesca M. Batidzirai |
---|---|
Format: | Article |
Language: | English |
Published: |
AOSIS
2016-07-01
|
Series: | Southern African Journal of Infectious Diseases |
Subjects: | |
Online Access: | https://sajid.co.za/index.php/sajid/article/view/87 |
Similar Items
-
Aspirin versus placebo for the treatment of venous leg ulcers—a phase II, pilot, randomised trial (AVURT)
by: Tilbrook Helen, et al.
Published: (2019-07-01) -
The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial
by: Phaik Yeong Cheah, et al.
Published: (2018-03-01) -
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
by: Dean A. Fennell, et al.
Published: (2022-10-01) -
Ondansetron for irritable bowel syndrome with diarrhoea: randomised controlled trial
by: David Gunn, et al.
Published: (2023-10-01) -
Protocol for the Metformin Aneurysm Trial (MAT): a placebo-controlled randomised trial testing whether metformin reduces the risk of serious complications of abdominal aortic aneurysm
by: Jonathan Golledge, et al.
Published: (2021-12-01)